ORZEYFUL (overporexton) Is Now Available in the US: What People With NT1 Need to Know
Big news for our community: ORZEYFUL™ (oveporexton) is now available by prescription in the United States. Takeda announced the launch on November 12, 2026, a few months after the FDA approved it in August. (Read our earlier breakdown of the FDA approval and ICER report here.)
Prefer to watch or listen? Take in this news however works best for you today.
🎥 Watch: short video overview
ORZEYFUL Explained: How It Works for Narcolepsy Type 1 (AI Video Overview)
🎧 ORZEYFUL Quick Listen: Headlines for People With NT1
Both generated with AI (NotebookLM) from Takeda’s announcement and this post, and reviewed by our team. Not medical advice. Please talk to your healthcare provider about your own treatment.
Prefer to read? Keep scrolling. 👇
What is ORZEYFUL?
ORZEYFUL is a tablet for adults with narcolepsy type 1 (narcolepsy with cataplexy). People with NT1 have lost most of the brain cells that make orexin, a chemical that helps keep us awake and stable. ORZEYFUL is the first medicine designed to switch on one of orexin’s receptors (orexin receptor 2), addressing that missing signal directly instead of treating symptoms one at a time. It doesn’t bring back the lost cells, but it helps make up for the signal they used to send.
How is it taken?
It comes in 1 mg and 2 mg tablets taken twice a day, the first dose when you wake up and the second 3 to 5 hours later. A lower 0.5 mg dose exists for people on certain other medicines. Grapefruit juice should be avoided during treatment.
What about side effects?
We want to be straight with you here. In the 12-week clinical studies, trouble sleeping (insomnia) and urinary side effects, like needing to go more often or more urgently, were common. Most insomnia started in the first week, and many cases resolved within a week. Increased saliva was also reported. Less commonly, it can raise a muscle enzyme called CPK, so tell your doctor about unexplained muscle pain, weakness, or dark urine. It’s a Schedule IV controlled substance, and it isn’t safe with certain medicines that are strong CYP3A inhibitors.
Who can get it?
Right now, adults with NT1 in the US, by prescription. It’s dispensed through Accredo Specialty Pharmacy, and Takeda Patient Support can help with insurance coverage and assistance options. It hasn’t been studied in people under 18, and it’s not approved for narcolepsy type 2 or idiopathic hypersomnia. Takeda is studying a separate medicine, TAK-360, for NT1, NT2, and IH.
Our take
For many in our community, this is a moment we’ve been hoping for. Orexin loss has defined NT1 for decades, and now there’s a treatment built around it. It won’t be right for everyone, and access will take time, but it’s a real step forward.
If you have NT1, bring it up at your next appointment and ask whether it could fit your treatment plan.
đź“– Learn more and see the full safety information: https://www.orzeyful.com
This post is for awareness only and isn’t medical advice. NapsForLife isn’t affiliated with Takeda. Please talk with your healthcare provider about your own treatment.
Comments